• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Krawtschuk Christopher

    11/19/24 7:59:53 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EGRX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Krawtschuk Christopher

    (Last) (First) (Middle)
    C/O EAGLE PHARMACEUTICALS, INC.
    50 TICE BLVD, SUITE 315

    (Street)
    WOODCLIFF LAKE NJ 07677

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/11/2024
    3. Issuer Name and Ticker or Trading Symbol
    EAGLE PHARMACEUTICALS, INC. [ EGRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Christopher Krawtschuk 11/19/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EGRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EGRX

    DatePrice TargetRatingAnalyst
    8/10/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    8/9/2023$26.00 → $17.00Neutral → Underweight
    Piper Sandler
    More analyst ratings

    $EGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

    WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") will be held on October 17, 2025. The specific time and place for the 2025 Annual Meeting will be specified in a notice and meeting materials to be provided to stockholders of record as of 5 p.m. Eastern Time on August 18, 2025, which is the record date for the meeting. The Company's bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at the following

    8/18/25 4:30:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

    WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. ("Blue Owl") (the "Agreement"), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs.   BENDEKA is a ready-to-dilute liquid, low-volume (50 mL) and short-time ten-minute infusion formulation of bendamustine. It is approved for the treatment of chronic lymphoc

    3/31/25 4:00:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

    3/21/25 4:30:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eagle Pharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

    8/10/23 7:32:29 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharma downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously

    8/9/23 10:15:46 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts resumed coverage on Eagle Pharma with a new price target

    RBC Capital Mkts resumed coverage of Eagle Pharma with a rating of Outperform and set a new price target of $52.00

    4/7/21 6:39:38 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Krawtschuk Christopher

    3 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

    11/19/24 7:59:53 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tarriff Scott covered exercise/tax liability with 2,119 shares, decreasing direct ownership by 0.46% to 460,621 units (SEC Form 4)

    4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

    3/1/24 4:40:02 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cahill Brian Joseph was granted 3,800 shares and covered exercise/tax liability with 1,589 shares, increasing direct ownership by 5% to 47,958 units (SEC Form 4)

    4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)

    2/29/24 8:23:05 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    SEC Filings

    View All

    SEC Form 15-12G filed by Eagle Pharmaceuticals Inc.

    15-12G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

    1/24/25 4:08:37 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Eagle Pharmaceuticals Inc.

    EFFECT - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

    12/10/24 12:15:03 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)

    12/2/24 4:17:10 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

    WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

    11/12/24 7:00:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

    WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. "We are very pleased with our acquisition of Acacia Pharma Group Plc ("Acacia") and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma's previous plans and positioning of the products. It is our belief that the two products were underinvested, both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment, in which access to d

    7/18/22 6:50:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Luciana ("Lu") Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration ("FDA" or "Agency"). "We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world's most complex challenges. Her

    5/3/21 6:50:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Financials

    Live finance-specific insights

    View All

    Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved an amendment to its previously disclosed limited duration stockholder rights plan (the "Rights Plan") to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in full force and effect in accordance with its terms. In general terms, the Rights Plan is designed to impose a penalty upon any person or group (an "Acquiring Person") that acquires beneficial ow

    3/21/25 4:30:00 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

    10/31/24 8:00:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eagle Delays Third Quarter 2023 Results and Conference Call

    WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b

    11/9/23 7:30:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

    11/14/24 11:34:47 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

    11/5/24 4:32:23 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

    SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)

    10/31/24 1:36:40 PM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care